Yngvild Nuvin Blaker

Oslo University Hospital — Norway

Medicine · Health Sciences

10h-index594citations33works8.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(19), CAR-T cell therapy research(16), Cancer Immunotherapy and Biomarkers(10), Cancer Genomics and Diagnostics(10), Immune Cell Function and Interaction(8)

Publications33 total

Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma
Blood Cancer Journal·2024· 8 citedOpen Access
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma
Blood Advances·2023· 24 citedOpen Access
Reduced Immune-Cell Infiltration in MHC Class I Negative DLBCL
Blood·2023· 1 cited
DIVERSITY OF INTRATUMORAL REGULATORY T CELLS IN B‐CELL NON‐HODGKIN LYMPHOMA
Hematological Oncology·2023Open Access
Supplementary Tables S1-S2 from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
2023Open Access
Data from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
2023· 1 citedOpen Access
Data from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
2023Open Access
Figure S1-S8 from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
2023Open Access
Supplementary Tables S1-S2 from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
2023Open Access
Figure S1-S8 from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
2023Open Access
Multi-Omics Profiling of Longitudinal Samples Reveals Early Genomic Changes in Follicular Lymphoma
Blood·2022· 1 cited
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma
Blood·2021· 121 citedOpen Access
Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma
Blood·2021· 1 cited
HIGH RISK AGGRESSIVE B‐CELL LYMPHOMA ON THE LIQUID BIOPSY
Hematological Oncology·2021Open Access
The DLBCL90 gene‐expression assay identifies double‐hit lymphomas with high sensitivity in patients from two phase II clinical trials with high‐risk diffuse large B‐cell lymphoma
eJHaem·2020· 4 citedOpen Access
Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma
Blood·2020· 2 cited
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
Blood Advances·2020· 13 citedOpen Access
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real‐world patients
British Journal of Haematology·2020· 22 citedOpen Access
Genomic Profiling of Circulating Tumor DNA Reveals Patterns of Response and Refractoriness in Aggressive B-Cell Lymphoma - a Nordic Lymphoma Group Correlative Study
Blood·2019· 1 cited
Inferior Outcomes for Older Patients in the Adolescent and Young Adult (AYA) Population with Burkitt Lymphoma Treated with Intensive Immunochemotherapy: An International Study of 108 Patients
Blood·2019
page 1 of 2Next →

Frequent Co-authors

Harald Holte(33), Erlend B. Smeland(26), June H. Myklebust(24), Klaus Beiske(22), Arne Kolstad(15), Kanutte Huse(15), Eva Kimby(14), Sarah E. Josefsson(13), Bjørn Østenstad(12), Hakan Köksal(10), Sébastien Wälchli(10), Marianne Brodtkorb(9), Judit Jørgensen(8), Sirpa Leppä(8), Ronald Levy(7), Ole Christian Lingjærde(7), Ankush Sharma(7), Chloé B. Steen(7), Baoyan Bai(7), Mette S. Førsund(7)